Offstream
news

The Medicines and Healthcare products Regulatory Agency approves the use of Pfizer's anti-viral oral drug Paxlovid for high-risk patients.
2021-12-31

The Food and Drug Administration grants emergency use authorization for Pfizer's antiviral COVID-19 oral pill named Paxlovid for at-risk people over the age of 12 years, becoming the first at-home oral treatment to be approved by the FDA.
2021-12-22

Pfizer says that their vaccine candidate is effective for children between the ages of 5 and 11 years.
2021-09-20

Switzerland signs an agreement with Pfizer to supply a total of 14 million doses of the Pfizer–BioNTech COVID-19 vaccine in 2022 and 2023, which also includes an option to supply an additional 7 million vaccine doses in subsequent years.
2021-08-25

The first 30,000 doses of the Pfizer-BioNTech vaccine are sent from Spain to Andorra after both governments reached an agreement earlier today.
2021-01-19

Iraq signs a preliminary deal to receive 1.5 million doses of the Pfizer-BioNTech vaccine Tozinameran. Ministry of Health spokesman Seif al-Badr says troops and the elderly will be prioritized for vaccinations.
2020-12-22

Saudi Arabia begins its vaccination campaign a day after it received two shipments of the Pfizer-BioNTech vaccine. More than 150,000 people have registered to receive the vaccine.
2020-12-17

Pfizer announces that it has submitted their vaccine for approval in India.
2020-12-5

Pfizer says that it will not seek emergency approval for its COVID-19 vaccine until after the upcoming election.
2020-10-16

Mexican Foreign Minister Marcelo Ebrard announces the country has signed agreements with AstraZeneca for 77.4 million, COVAX for 51.57 million, CanSino Biologics for 35 million, and Pfizer for 34.4 million vaccine doses, respectively. The vaccines by Pfizer, AstraZeneca, and the COVAX plan require two doses, whereas the CanSino product requires one dose.
2020-10-13